Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) EBITDA Margin (2016 - 2021)

Historic EBITDA Margin for Neurocrine Biosciences (NBIX) over the last 11 years, with Q3 2021 value amounting to 7.5%.

  • Neurocrine Biosciences' EBITDA Margin rose 303200.0% to 7.5% in Q3 2021 from the same period last year, while for Sep 2021 it was 3.41%, marking a year-over-year decrease of 57000.0%. This contributed to the annual value of 5.12% for FY2019, which is 4600.0% up from last year.
  • Per Neurocrine Biosciences' latest filing, its EBITDA Margin stood at 7.5% for Q3 2021, which was up 303200.0% from 14.54% recorded in Q2 2021.
  • Neurocrine Biosciences' EBITDA Margin's 5-year high stood at 33.95% during Q3 2018, with a 5-year trough of 954.43% in Q2 2017.
  • In the last 5 years, Neurocrine Biosciences' EBITDA Margin had a median value of 13.23% in 2021 and averaged 55.04%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first surged by 9492400bps in 2018, then crashed by -475000bps in 2020.
  • Quarter analysis of 5 years shows Neurocrine Biosciences' EBITDA Margin stood at 5.9% in 2017, then skyrocketed by 135bps to 13.84% in 2018, then fell by 0bps to 13.83% in 2019, then crashed by -265bps to 22.82% in 2020, then surged by 133bps to 7.5% in 2021.
  • Its EBITDA Margin was 7.5% in Q3 2021, compared to 14.54% in Q2 2021 and 13.23% in Q1 2021.